Targeting microRNAs in heart failure

Trends in Cardiovascular Medicine

Volumn 26, Issue 2, 2016, Pages 99-110

  Duygu, Burcu ^a   de Windt, Leon J ^a   da Costa Martins, Paula A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Heart failure; MicroRNA; Therapeutics

Indexed keywords

ANTAGOMIR; MICRORNA; BIOLOGICAL MARKER; OLIGONUCLEOTIDE;

ANGIOGENESIS; DIAGNOSTIC VALUE; GENE TARGETING; GENE THERAPY; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; INFLAMMATION; METABOLIC BALANCE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CLASSIFICATION; EXPERIMENTAL THERAPY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; TRENDS;

ANIMALS; BIOMARKERS; HEART FAILURE; HUMANS; MICRORNAS; MODELS, GENETIC; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES; THERAPIES, INVESTIGATIONAL;

EID: 84959145131     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.05.008     Document Type: Review

References (73)

1. Johnson F.L. Pathophysiology and etiology of heart failure. Cardiol Clin 2014, 32:9-19. [vii].
2. Kehat I., Molkentin D.J. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010, 122:2727-2735.
3. Saxena A., Tabin C.J. miRNA-processing enzyme Dicer is necessary for cardiac outflow tract alignment and chamber septation. Proc Natl Acad Sci U S A 2010, 107:87-91.
4. da Costa Martins P.A., Bourajjaj M., Gladka M., Kortland M., van Oort R.J., Pinto Y.M., et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008, 118:1567-1576.
5. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
6. Patrick D.M., Montgomery R.L., Qi X., Obad S., Kauppinen S., Hill J.A., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010, 120:3912-3916.
7. Dong S., Cheng Y., Yang J., Li J., Liu X., Wang X., et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009, 284:29514-29525.
8. Abonnenc M., Nabeebaccus A.A., Mayr U., Barallobre-Barreiro J., Dong X., Cuello F., et al. Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ Res 2013, 113:1138-1147.
9. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008, 105:13027-13032.
10. Roncarati R., Viviani Anselmi C., Losi M.A., Papa L., Cavarretta E., Da Costa Martins P., et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2014, 63:920-927.
11. Liu N., Bezprozvannaya S., Williams A.H., Qi X., Richardson J.A., Bassel-Duby R., et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008, 22:3242-3254.
12. Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009, 104:170-178. [6p following 178].
13. Shan H., Zhang Y., Lu Y., Zhang Y., Pan Z., Cai B., et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009, 83:465-472.
14. Castoldi G., Di Gioia C.R., Bombardi C., Catalucci D., Corradi B., Gualazzi M.G., et al. miR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol 2012, 227:850-856.
15. Nam Y.J., Song K., Luo X., Daniel E., Lambeth K., West K., et al. Reprogramming of human fibroblasts toward a cardiac fate. Proc Natl Acad Sci U S A 2013, 110:5588-5593.
16. Pan Z., Sun X., Shan H., Wang N., Wang J., Ren J., et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. Circulation 2012, 126:840-850.
17. Wang S., Olson E.N. AngiomiRs-key regulators of angiogenesis. Curr Opin Genet Dev 2009, 19:205-211.
18. Doebele C., Bonauer A., Fischer A., Scholz A., Reiss Y., Urbich C., et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010, 115:4944-4950.
19. Pullamsetti S.S., Doebele C., Fischer A., Savai R., Kojonazarov B., Dahal B.K., et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 2012, 185:409-419.
20. Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324:1710-1713.
21. Hinkel R., Penzkofer D., Zuhlke S., Fischer A., Husada W., Xu Q.F., et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 2013, 128:1066-1075.
22. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008, 15:261-271.
23. Long G., Wang F., Duan Q., Chen F., Yang S., Gong W., et al. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci 2012, 8:811-818.
24. Fiedler J., Jazbutyte V., Kirchmaier B.C., Gupta S.K., Lorenzen J., Hartmann D., et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011, 124:720-730.
25. Meloni M., Marchetti M., Garner K., Littlejohns B., Sala-Newby G., Xenophontos N., et al. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol Ther 2013, 21:1390-1402.
26. Hu S., Huang M., Li Z., Jia F., Ghosh Z., Lijkwan M.A., et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010, 122(suppl 11):S124-S131.
27. Endo K., Naito Y., Ji X., Nakanishi M., Noguchi T., Goto Y., et al. MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull 2013, 36:48-54.
28. Halkein J., Tabruyn S.P., Ricke-Hoch M., Haghikia A., Nguyen N.Q., Scherr M., et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013, 123:2143-2154.
29. Wang X., Ha T., Liu L., Zou J., Zhang X., Kalbfleisch J., et al. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc Res 2013, 97:432-442.
30. Boon R.A., Iekushi K., Lechner S., Seeger T., Fischer A., Heydt S., et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013, 495:107-110.
31. Bernardo B.C., Gao X.M., Winbanks C.E., Boey E.J., Tham Y.K., Kiriazis H., et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A 2012, 109:17615-17620.
32. Icli B., Wara A.K., Moslehi J., Sun X., Plovie E., Cahill M., et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res 2013, 113:1231-1241.
33. Dirkx E., Gladka M.M., Philippen L.E., Armand A.S., Kinet V., Leptidis S., et al. Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol 2013, 15:1282-1293.
34. Wahlquist C., Jeong D., Rojas-Munoz A., Kho C., Lee A., Mitsuyama S., et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014, 508:531-535.
35. Thum T., Galuppo P., Wolf C., Fiedler J., Kneitz S., van Laake L.W., et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007, 116:258-267.
36. Varga Z.V., Kupai K., Szucs G., Gaspar R., Paloczi J., Farago N., et al. MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart. J Mol Cell Cardiol 2013, 62:111-121.
37. da Costa Martins P.A., Salic K., Gladka M.M., Armand A.S., Leptidis S., el Azzouzi H., et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010, 12:1220-1227.
38. El Azzouzi H., Leptidis S., Dirkx E., Hoeks J., van Bree B., Brand K., et al. The hypoxia-inducible microRNA cluster miR-199a approximately 214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation. Cell Metab 2013, 18:341-354.
39. Ikeda S., He A., Kong S.W., Lu J., Bejar R., Bodyak N., et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009, 29:2193-2204.
40. Tritsch E., Mallat Y., Lefebvre F., Diguet N., Escoubet B., Blanc J., et al. An SRF/miR-1 axis regulates NCX1 and annexin A5 protein levels in the normal and failing heart. Cardiovasc Res 2013, 98:372-380.
41. Kumarswamy R., Lyon A.R., Volkmann I., Mills A.M., Bretthauer J., Pahuja A., et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J 2012, 33:1067-1075.
42. Elia L., Contu R., Quintavalle M., Varrone F., Chimenti C., Russo M.A., et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 2009, 120:2377-2385.
43. Karakikes I., Chaanine A.H., Kang S., Mukete B.N., Jeong D., Zhang S., et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2013, 2:e000078.
44. Varrone F., Gargano B., Carullo P., Di Silvestre D., De Palma A., Grasso L., et al. The circulating level of FABP3 is an indirect biomarker of microRNA-1. J Am Coll Cardiol 2013, 61:88-95.
45. Besser J., Malan D., Wystub K., Bachmann A., Wietelmann A., Sasse P., et al. MiRNA-1/133a clusters regulate adrenergic control of cardiac repolarization. PLoS One 2014, 9:e113449.
46. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613-618.
47. Castaldi A., Zaglia T., Di Mauro V., Carullo P., Viggiani G., Borile G., et al. MicroRNA-133 modulates the β1-adrenergic receptor transduction cascade. Circ Res 2014, 115:273-283.
48. Matkovich S.J., Wang W., Tu Y., Eschenbacher W.H., Dorn L.E., Condorelli G., et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010, 106:166-175.
49. Feng B., Chen S., George B., Feng Q., Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 2010, 26:40-49.
50. Chen S., Puthanveetil P., Feng B., Matkovich S.J., Dorn G.W., Chakrabarti S. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med 2014, 18:415-421.
51. Chavali V., Tyagi S.C., Mishra P.K. MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes. Biochem Biophys Res Commun 2012, 425:668-672.
52. Montgomery R.L., Hullinger T.G., Semus H.M., Dickinson B.A., Seto A.G., Lynch J.M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011, 124:1537-1547.
53. Lin Z., Murtaza I., Wang K., Jiao J., Gao J., Li P.F. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A 2009, 106:12103-12108.
54. Wang K., Lin Z.Q., Long B., Li J.H., Zhou J., Li P.F. Cardiac hypertrophy is positively regulated by MicroRNA miR-23a. J Biol Chem 2012, 287:589-599.
55. Ganesan J., Ramanujam D., Sassi Y., Ahles A., Jentzsch C., Werfel S., et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 2013, 127:2097-2106.
56. Ucar A., Gupta S.K., Fiedler J., Erikci E., Kardasinski M., Batkai S., et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 2012, 3:1078.
57. Raisch J., Darfeuille-Michaud A., Nguyen H.T. Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol 2013, 19:2985-2996.
58. Seok H.Y., Chen J., Kataoka M., Huang Z.P., Ding J., Yan J., et al. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res 2014, 114:1585-1595.
59. Heymans S., Corsten M.F., Verhesen W., Carai P., van Leeuwen R.E., Custers K., et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013, 128:1420-1432.
60. Gebert L.F., Rebhan M.A., Crivelli S.E., Denzler R., Stoffel M., Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res 2014, 42:609-621.
61. Sanchez-Nino M.D., Ortiz A. HCV infection and miravirsen. N Engl J Med 2013, 369:877-878.
62. Liu Y., Li L., Su Q., Liu T., Ma Z., Yang H. Ultrasound-targeted microbubble destruction enhances gene expression of microRNA-21 in swine heart via intracoronary delivery. Echocardiography 2015, 00:1-10.
63. Gill S.L., O'Neill H., McCoy R.J., Logeswaran S., O'Brien F., Stanton A., et al. Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro model. Technol Health Care 2014, 22:37-51.
64. Wang H., Jiang Y., Peng H., Chen Y., Zhu P., Huang Y. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. Adv Drug Deliv Rev 2015, 81:142-160.
65. Zhang Y., Wang Z., Gemeinhart R.A. Progress in microRNA delivery. J Control Release 2013, 172:962-974.
66. Davis S., Propp S., Freier S.M., Jones L.E., Serra M.J., Kinberger G., et al. Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 2009, 37:70-77.
67. Kinet V., Halkein J., Dirkx E., Windt L.J. Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-to-cell RNA communication. Front Genet 2013, 4:214.
68. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
69. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3:e3694.
70. Zernecke A., Bidzhekov K., Noels H., Shagdarsuren E., Gan L., Denecke B., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009, 2:ra81.
71. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011, 108:5003-5008.
72. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.
73. Li R.C., Tao J., Guo Y.B., Wu H.D., Liu R.F., Bai Y., et al. In vivo suppression of microRNA-24 prevents the transition toward decompensated hypertrophy in aortic-constricted mice. Circulation research 2013, 112:601-605.